The proinflammatory role of lipoxygenases in rheumatoid arthritis

Jarosław Bryda¹, Sławomir Wątroba²

¹ Department of Veterinary Hygiene, Voivodship Veterinary Inspectorate, Lublin, Poland
² Department of Neonatology and Neonatal Intensive Care Unit, Independent Public Healthcare, Puławy, Poland


Abstract

Introduction. Rheumatoid arthritis (RA) is a chronic, systemic disease of connective tissue with autoimmune background. There is a lack of knowledge about the direct pathophysiological cause of RA formation. The involvement of lipoxygenase (LOX) in arachidonic acid (AA) metabolism can have a significant impact on the occurrence of RA. Lipid mediators play a significant role, inducing structural and metabolic changes in cells that initiate the activation of proinflammatory pathways and immune responses.

Objective. The purpose of this review is to analyze the involvement of LOX in the etiopathogenesis of RA, with particular emphasis on 5-LOX and 15-LOX, as well as the characteristics of LOX enzymatic activity and identification of the role of AA metabolites in the inflammatory reaction process.

State of knowledge. The effects of oxidative activity of LOX and dysfunctions of intracellular antioxidant systems lead to disturbance of redox homeostasis. The observed consequence of these phenomena are aberrations in the functioning of the immune system and accompanying inflammation. In RA studies, increased activity of 5-LOX and its reaction products was observed, such as leukotrienes B₄ (LTB₄) and 5-hydroxyeicosatetraenoic acid (5-HETE) in patients. A significant influence on the progression of RA is also associated with overexpression of 15-LOX, which leads to inhibition of chondrocyte proliferation and their apoptosis.

Conclusion. The activity of the oxidative enzyme LOX is involved in the formation of lipid mediators responsible for inducing inflammation. The effects of the action of LOX may be disorders of the immune system that contribute to the development of RA.

Key words
lipoxygenase, rheumatoid arthritis, inflammation, leukotrienes, metalloproteinases

INTRODUCTION

Lipoxygenases (LOX, EC 1.13.11.) are oxidoreductases class enzymes, a subclass of dioxygenases, commonly found in plant and animal organisms as well as some fungi, algae and cyanobacteria [1]. They catalyze the oxidation reactions of polyunsaturated fatty acids (PUFAs) containing cis, cis-1,4-pentadienoic bonds, and their esters till conjugated unsaturated fatty acids and lipid hydroperoxides. The substrates of these reactions are arachidonic acid (AA), commonly found in the lipids of mammalian cell membranes, and linoleic (LA) and linolenic acids (ALA) found in plant organisms [2]. In plants, the activity of LOX leads to the formation of oxylipines involved in the regulation of many physiological processes, including germination, defence reactions to stress, or the synthesis of plant hormones [3]. In humans, the same as in mice, six LOX isoforms have been identified (15-LOX, 15-LOX-2, 12-LOX, 12R-LOX, eLOX-3, 5-LOX). In mammals, these enzymes are expressed in epithelial, immune and neoplastic cells, displaying a variety of biological functions. Their effects are also observed in inflammation, skin disorders and cancer [4].

OBJECTIVE

The aim of this brief review was to present the role of 5-LOX and 15-LOX and the products of their catalyzed reactions as pro-inflammatory mediators in the pathophysiology of RA. Important reports on the activity of lipoxygenases in RA in in vitro and in vivo models have been highlighted. LOX, their catalytic activity, activation mechanism and biologically active reaction products in mammalian organisms are also briefly characterized.

MATERIALS AND METHOD

Structure and mechanism of the LOX reaction. LOX are composed of single corrugated polypeptide chains with a molecular mass of 75–80 kDa in animals and 94–104 kDa in plants. In their structure they have two domains, a shorter N-terminal β-cylindrical and a longer C-terminal helictic containing the active site of the enzyme. The longer domain is surrounded by a single atom of non-heme iron [1, 5].

The best known and characterized is LOX-1 derived from soybeans. It serves as a biochemical model for research on the mechanism of reactions carried out by LOX. This is due to the possibility of the relatively easy isolation of this enzyme and its considerable stability [6]. The structure of mammalian LOX enzymes seems to be similar. However, it should be noted to each isoform has unique properties, such as substrate specificity [4, 7].
The structure of model soybean LOX-1 shows the presence of 839 amino acid residues, which include two domains. Domain I contains 146 residues and the N-terminal amino acid, domain II consists of 693 residues and a C-terminal amino acid. LOX is a metalloprotein containing at the centre of the C-terminal domain an iron atom that is coordinated with five endogenous ligands (His 499, His 504, His 690, Ile 839, Asn 694), and a coordination site for water binding, particularly important for catalytic activity. In the inactive form of the enzyme, iron is present in the second oxidation state, which under the influence of oxygen undergoes activation transforms to Fe (+3).[5, 8].

Activation of the enzyme requires the presence of hydroperoxides of fatty acids or hydrogen peroxide as catalysts, at which the participation the oxidation of the iron atom occurs. The presence of hydroperoxides is the result of the autooxidation reaction. Indirectly, they can also be produced by the action of small amounts of active LOX. As a result of activating the enzyme, the resulting reaction products are used to activate further enzyme particles, and in this way the proper hydroperoxide formation takes place [1, 2, 9]. The first stage of the reaction is removal of a hydrogen atom as proton from the substrate, pro-S from the methylene group located between the double bonds, resulting in the formation of a fatty acid radical, and there is iron reduction at the active site of the enzyme (Fig.1.1). The second stage of the catalytic reaction takes place in the anaerobic or aerobic cycle. In the absence of oxygen, the radical is dissociated from the enzyme and the radical becomes a substrate in further reaction processes. In aerobic conditions, the radical is dissociated from the enzyme and the radical becomes a substrate in free radical reactions (FRR) (Fig.1.5). In aerobic conditions, the catalytic cycle takes place in the anaerobic or aerobic cycle. In the absence of oxygen, the radical is dissociated from the enzyme and the radical becomes a substrate in free radical reactions (FRR) (Fig.1.5). In aerobic conditions, the catalytic cycle takes place in the anaerobic or aerobic cycle. In the absence of oxygen, the radical is dissociated from the enzyme and the radical becomes a substrate in free radical reactions (FRR) (Fig.1.5).

Biological products of LOX in mammals. LOX play an important role in mammalian organisms, which include regulation of redox cellular homeostasis, gene expression and participation in cell proliferation and differentiation. Their activity also contributes to the formation of inflammation, involvement in the pathophysiology of metabolic, neurodegenerative, immunological, hyperproliferative and infectious diseases. They initiate the formation of free radicals contributing to harmful lipid oxidation reactions. Recently, the role of the main products of metabolism catalyzed by LOX in monitoring the progression of chronic kidney disease (CKD) is also underlined. [4, 12–15].

LOX are involved in inflammatory reactions of the body, contributing to the formation of mediators of the inflammatory process. A significant part of these compounds originates from PUFAs [16]. The substrate for reactions catalysed by LOX in mammalian cells is AA that is released from membrane phospholipids by phospholipase A2 (PLA2s). As a result of the action of LOX, non-cyclic compounds, such as leukotrienes (LT), 5-, 12- and 15-hydroperoxyeicosatetraenoic acids (HpETE) and hydroxyeicosatetraenecids (HETE), are formed [17, 18]. LT are formed in various types of leukocytes and other cells with immune competence. Their biosynthesis takes place in the 5-LOX enzymatic pathway from free AA. The first stage of the reaction is oxygenation of AA to 5S-HpETE, followed by conversion of 5S-HpETE to LT-A4. LT can be divided into two classes: peptido-LTs – leukotrienes C4, D4, E4 (LT-C4, LTD4, LTE4) and peptide-free-LTs – leukotriene B4 (LTB4) [12]. The resulting eicosanoids are characterized by high biological activity. They stimulate strong allergic and inflammatory reactions, form clots, contribute to atherosclerotic changes, and are responsible for the growth of cancerous tissue in such organs as the prostate and colon [17, 18].

Some reaction products catalyzed by LOX, such as lipoxins A4 (LXA4) and its epimer 15-epi-LXA4, may also have anti-inflammatory activity. This action is based on the stimulation of the ALX receptor (ALX-r), which occurs particularly in leukocytes and leads to suppression of the inflammatory response. The action of lipoxins in in vivo studies show that they are unstable and they are enzymatically inactivated [16, 19].

In addition to participating in the production of biologically active lipid mediators, LOX may also be active by two other mechanisms: 1-modifications of protein-lipid complexes, leading to impaired cell membrane function and 2- by modifying cellular redox homeostasis affecting gene expression [12, 17].

Rheumatoid arthritis characteristics and diagnostic criteria. Rheumatoid arthritis (RA) is a chronic, immunologically dependent connective tissue disease, characterized by a progressive, non-specifically symmetrical, inflammatory reaction that progresses in the synovium of the affected joint. Inflammation of the synovium, along with the progression of the disease, is generalized and gradually involves the structure of the entire joint along with tendinous sheath and synovial bursa [20, 21]. Due to the frequent occurrence of extra-articular changes and systemic complications, the disease often leads to disability [22].

RA affects about 0.5%-2% of the world’s population [23], and in Poland, RA affects about 0.9% of the population [24]. The highest number of cases is recorded in the fourth and fifth decades of life, although the first symptoms of the disease may occur between the 2nd and the 3rd decade of life. RA is about four times more common in women [25].

Figure 1. Catalytic cycle of the LOX reaction [11 modified].
Joint changes in RA are symmetrical and usually involve the small hand joints. Typically, they involve the metacarpophalangeal joints, proximal interphalangeal joints and wrist joints, often leading to carpal tunnel syndrome. Subsequently, inflammatory changes include the knee, ankle, shoulder and toe joints, as well as the joints of the cervical spine, which may cause subluxation and secondary neurological symptoms [26, 27]. The most serious organ complications in the course of RA are vasculitis, pulmonary fibrosis and reactive amyloidosis [26, 28, 29].

The diagnostic criteria of RA developed in 2010 by the American College of Rheumatology and European League Against Rheumatism are summarized in Table 1 [30].

### Table 1. Diagnostic criteria of RA (American College of Rheumatology and European League Against Rheumatism, 2010) [30]

<table>
<thead>
<tr>
<th>Target population (who should be tested?)</th>
<th>Patients who:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) have at least one joint with definite clinical synovitis (swelling)*</td>
<td>2) with the synovitis not better explained by another disease</td>
</tr>
</tbody>
</table>

Classification criteria for RA (score-based algorithm: add score of categories A – D; a score of ≥ 6 out of 10 is needed for classification of a patient as having definite RA):

<table>
<thead>
<tr>
<th>A. Joint involvement § Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 large joint</td>
</tr>
<tr>
<td>1 – 10 large joints</td>
</tr>
<tr>
<td>1 – 3 small joints (with or without involvement of large joints)</td>
</tr>
<tr>
<td>4 – 10 small joints (with or without involvement of large joints)</td>
</tr>
<tr>
<td>&gt; 10 joints (at least one small joint)**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. Serology (at least one test result is needed for classification) †† Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative RF and negative ACPA</td>
</tr>
<tr>
<td>Low positive RF or low positive ACPA</td>
</tr>
<tr>
<td>High positive RF or high positive ACPA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. Acute phase reactants (at least one test result is needed for classification) ‡‡ Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal CRP and normal ESR</td>
</tr>
<tr>
<td>Abnormal CRP or normal ESR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D. Duration of symptoms §§ Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 6 weeks</td>
</tr>
<tr>
<td>≥ 6 weeks</td>
</tr>
</tbody>
</table>

ACPA – anti-citrullinated protein antibody, CRP – C-reactive protein, ESR – erythrocyte sedimentation rate, RA – rheumatoid arthritis

* Criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease typical of RA with a history compatible with prior fulfillment of the 2010 criteria should be classified as having RA. Patients with long-standing disease, including those whose disease is inactive (with or without treatment), who, based on retrospectively available data, have previously fulfilled the 2010 criteria should be classified as having RA.

† – Although patients with a score of less than 6 out of 10 are not classifiable as having RA, their status may be reassessed, and the criteria might be fulfilled cumulatively over time.

‡ – Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints are excluded from assessment. Categories of joint distribution are classified according to the location and number of involved joints, with placement into the highest category possible based on the pattern of joint involvement.

¶ – “Small joints” refers to shoulders, elbows, hips, knees, and ankles.

†† – If at least one of the involved joints must be a small joint, the other joints can include any combination of large and additional small joints, as well as other joints not specifically listed elsewhere (e.g., temporomandibular, acromioclavicular, sternoclavicular).

‡‡ – “Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal joints, distal interphalangeal joints, thumb interphalangeal joints, and wrists.

** – At least one of the involved joints must be a small joint.

§ – Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints are excluded from assessment. Categories of joint distribution are classified according to the location and number of involved joints, with placement into the highest category possible based on the pattern of joint involvement.

It is important to note that the role of LTB4 in the development of this disease has been demonstrated in mice without 5-LOX or LTB4, in which they were shown to be protected from RA development, which proves the important role of LTB4 in the development of this disease.

The role of 5-LOX in RA has been demonstrated in studies conducted by Gheorge et al. [49] on a group of six RA patients and five patients with osteoarthritis (OA). In this study, although it was performed on a low number group, 5-LOX was highly expressed in the synovial tissues of RA and those with no RA [49]. Interesting conclusions were also made by Chen et al. [50], conducted in mice without 5-LOX or LTB4, in which they were shown to be protected from RA development, which proves the important role of LTB4 in the development of this disease.
of RA patients compared to patients with OA. Using dual immunofluorescence, the highest expression of the enzyme was found in CD163 + macrophages, CD68 + macrophages, CD66b + neutrophils and in tryptase-positive mast cells. However, no 5-LOX expression was found in synovial fibroblasts, T lymphocytes and B lymphocytes. In patients with OA 5-LOX showed little expression, which is in agreement with the Ahmadzadeh et al. [51] study, which found low LTB4 in liquid synovial fluid and a low degree of infiltration of the synovial membrane with inflammatory cells in patients with OA. In a study conducted by Goetzl et al. [52], LTB4 showed a chemotactic effect on neutrophils and eosinophils at a concentration of 3 ng/ml and 5-HETE at a concentration of 1000 ng/ml, which proves their significant role in the induction of local inflammatory response, even at small concentrations in the synovial fluid.

LOX-15 in rheumatoid arthritis. Currently, there are a limited number of publications that promote the role of 15-LOX in chronic inflammation, but its role in the pathophysiology of inflammation and modulation of immunity has long been recognized. In humans, 15-LOX occurs in two isoforms — as 15-LOX and 15-LOX-2, which differ in tissue localization. 15-LOX is predominantly found in macrophages, dendritic cells, eosinophils and the skin, whereas 15-LOX-2 is in the skin, cornea, alveolar macrophages and the prostate gland [49, 53].

Referring to the biological functions of 15-LOX-2, in the conducted studies, its role in the pathophysiology of atherosclerosis in humans and animals is raised. Significant 15-LOX-2 expression was demonstrated in macrophages of atherosclerotic plaques in both humans and experimental mice [54, 55]. In mice with blocked 15-LOX-2 expression, so-called defective atherosclerosis was observed, which proves that in the mouse atherosclerotic model, high activity of 15-LOX-2 is necessary for the development of the disease [55].

It was also proven in numerous studies that the 15-LOX-2 performs the atyproliferative function, stating a reduction the activity of 15-LOX-2 in epithelial-derived tumors [56–58]. In addition, 15-LOX-2 is involved in the production of docosahexaenoic acid (DHA) anti-inflammatory neuroprotectin D1, for which, however, at the present state of knowledge, no effects in the pathophysiology of rheumatic diseases have been proved [59, 60].

15-LOX is a lipid peroxide enzyme and has a proven pronounced pro-inflammatory effect. It converts AA to 15S-HpETE, which is highly unstable in the human body and is further converted to 15-HETE [49]. In addition, the participation of 15-LOX in the metabolism of AA has been found in small pro-inflammatory molecules, which work by increasing capillary permeability through a damaging effect on endothelial cells, as demonstrated in in vitro studies [61].

In studies comparing the expression of 15-LOX in the synovium of patients suffering from RA and OA, it was shown that it was significantly higher in RA patients. The cited study analyzed the synovium fragments obtained by biopsy from six RA patients and from five OA patients. The rabbit polyclonal anti-human 15-LOX isoform antibodies were used in the immunohistochemical diagnosis [49]. Positive staining for 15-LOX was detected in both connective tissue and blood vessel cells, as well as in mononuclear and neutrophil cells, accounting for nearly 70% of the total pool of synovial fluid cells in RA patients. The synovium tissue of patients suffering from OA showed a small expression of the 15-LOX isoform. Interestingly, in the above study it was shown that after the corticosteroid local application there is no reduction of 15-LOX expression, with simultaneous pronounced reduction of 5-LOX expression. In a study conducted by Liagre et al. [62], expression of 15-LOX in vascular endothelial cells was demonstrated; moreover, a correlation between 15-LOX expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity was demonstrated, which is important in enhancing chemotaxis of inflammatory immune cells into diseased tissues. Interestingly, despite the significant expression of 15-LOX in the synovium, patients suffering from RA did not correlate with the concentration of 15-HETE in synovial fluid. In addition to enhancing immune cell chemotaxis to the focus of inflammation through NF-kB induction, the proinflammatory action of 15-LOX in RA relies on increasing vascular permeability, increasing TNF-α expression in vascular smooth muscle, as well as inhibiting proliferation and induction of chondrocyte apoptosis [63]. Despite the proven proinflammatory effect, it should be emphasized that the reaction products catalyzed by 15-LOX may paradoxically exhibit anti-inflammatory properties in RA as, for example, in the case of lipoxins. There is no doubt that 15-LOX plays a significant role in the pathophysiology of RA which, however, due to its dual action (both pro-inflammatory and potentially anti-inflammatory), requires further research [49, 64].

CONCLUSIONS

RA is a chronic autoimmune disease characterized by damage to the synovium, tendon sheaths and synovial tissues. In the course of the disease, which affects about 0.5% – 2.0% of the population, there are often organ complications and numerous extra-articular changes that lead to disability. In the pathogenesis of RA, an important role is attributed to dysfunctions of the immune system, consisting in the induction of antibodies directed against the tissues of their own body. In the chronic inflammatory process, they also play the role of transformation of arachidonic acid through COX and LOX.

In the presented study, 5-LOX and 15-LOX have been given special attention in the pathophysiology of RA. Among the reaction products catalyzed by 5-LOX, LTB4 and 5-HETE are the largest contributors to the pathogenesis of RA. LTB4 activity is manifested by the activation of phospholipase A2, increasing the production of oxygen free radicals, intensification of leukocyte and macrophage chemotaxis, as well as the increase of leukocyte diapedesis into the extravascular space. LTB4 is also a negative regulator of bone turnover, intensifies bone tissue degradation and significantly inhibits its formation.

15-LOX is a lipid peroxide enzyme and has proven proinflammatory action. In vitro studies have demonstrated the involvement of 15-LOX in the metabolism of AA to small molecules, the effect of which is to increase capillary permeability. The pro-inflammatory activity of 15-LOX in RA also involves increasing the expression of TNF-α in vascular smooth muscle, as well as inhibiting proliferation and induction of chondrocyte apoptosis. A correlation between the expression of 15-LOX and NF-kB activity was also demonstrated, which is important in enhancing the chemotaxis of inflammatory cells to the tissues involved in the disease process. Interestingly, despite the proven pro-
inflammatory effect, the products of reactions catalyzed by 15-LOX may also have anti-inflammatory properties, as is the case with lipoxins.

There is no doubt that LOX plays an important role in the pathophysiology of RA, but their participation in the case with lipoxins. 15-LOX may also have anti-inflammatory properties, as is

15-LOX may also have anti-inflammatory properties, as is

inflammatory effect, the products of reactions catalyzed by 15-LOX may also have anti-inflammatory properties, as is the case with lipoxins.

There is no doubt that LOX plays an important role in the pathophysiology of RA, but their participation in the case with lipoxins. 15-LOX may also have anti-inflammatory properties, as is

REFERENCES


